FIELD: biotechnology.
SUBSTANCE: following is described: the use of antimicrobial cyclic lipopeptides as membrane fusion inhibitors, wherein the lipopeptides are selected from the group consisting of aculeacin A, anidulafungin, caspofungin, fengycin, iturin A, mycosubtilin, and syringotoxin B. In one embodiment, the use of lipopeptides to inhibit fusion of SARS-CoV-2 viral particles with cells is described.
EFFECT: invention expands the arsenal of agents that inhibit the fusion of cell membranes.
2 cl, 5 dwg, 4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION HAVING A HIGH CONCENTRATION OF ITURIN LIPOPEPTIDES | 2018 |
|
RU2801578C1 |
SURFACTANTS OF Bacillus sp. AND COMPOSITION WITH THEM | 2012 |
|
RU2605625C2 |
METHOD FOR OBTAINING THE TOTAL FRACTION OF LIPOPEPTIDES OF BACTERIA BACILLUS SUBTILIS MG-8 VKPM B-12476 AND ITS USE AS A PROPHYLACTIC AGAINST DISEASES OF POULTRY | 2021 |
|
RU2770481C1 |
STRAIN OF HYBRID ANIMAL CELLS MUS MUSCULUS 2E1B5 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE RECEPROT-BINDING DOMAIN OF PROTEIN S OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2771288C1 |
TEST SYSTEM FOR DETECTION OF SARS-COV-2 VIRUS RNA IN BIOMATERIAL FROM ANIMALS, FOOD AND ENVIRONMENTAL OBJECTS BY THE POLYMERASE CHAIN REACTION METHOD IN REAL TIME | 2021 |
|
RU2756474C1 |
CYCLODECAPEPTIDE ANTIBIOTIC LATEROCIDIN WITH BROAD SPECTRUM OF ANTAGONISTIC EFFECT, STRAIN OF BACTERIUM BREVIBACILLUS LATEROSPORUS ELICITING BROAD SPECTRUM OF ANTAGONISTIC EFFECT AS PRODUCER OF ANTIBIOTIC LATEROCIDIN | 2002 |
|
RU2229520C1 |
MODIFIED ANTISENSE OLIGONUCLEOTIDE AGAINST SARS-CoV-2 | 2020 |
|
RU2750584C1 |
METHOD FOR PHYSICAL THERAPY OF ANOSMIA AFTER CORONAVIRUS INFECTION | 2021 |
|
RU2751823C1 |
METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE HUMAN COMPLEMENT SYSTEM FOR PREDICTING THE SEVERITY OF THE COURSE OF A SYSTEMIC INFLAMMATORY REACTION | 2021 |
|
RU2756764C1 |
METHOD FOR DETECTING INFECTION OF HUMANS AND ANIMALS WITH SARS CoV 2 AND A DIAGNOSTIC KIT FOR IMPLEMENTING THE METHOD | 2021 |
|
RU2776295C1 |
Authors
Dates
2023-09-04—Published
2022-11-09—Filed